UNDERVALUED OTC STOCKS #3 RLFTF
Relief Therapeutics Holding AG is the largest company from today’s picks ($600+ million market cap), and we still think it’s the most undervalued from this list.
We first discussed RLFTF in August last year, sharing our bullish stance on the OTC stock. The company did really well in the following months, but its share price eventually started to correct, and RLFTF is currently trading at 20 cents. Nevertheless, we treat his as a consolidation period and think that Relief Therapeutics has strong fundamentals.
Undervalued OTC stocks RLFTF
RLFTF’s main product is a compound that it promotes as RLF-100TM (aviptadil), which the company proposes in the treatment of COVID-19-related lung injury. At the end of April, Relief Therapeutics and German-based AdVita Lifescience GmbH announced the start of the phase 2 trial to assess the efficiency of RFL-100TM for the prevention of COVID-19-induced acute respiratory distress syndrome (ARDS).
The trial (NCT 04536350) is a randomized, double-blind, placebo-controlled phase 2 trial that is carried out at several clinical sites in Switzerland. The study will enroll 80 patients, who will receive either RLF-100 together with standard of care or placebo plus standard of care.
Prof. Dr. Joerg D. Leuppi, M.D., Ph.D., lead investigator of the study, explained: